Salivary Gland Pathology. Группа авторов

Salivary Gland Pathology - Группа авторов


Скачать книгу
Photo depicts a 6-year-old African female with AIDS showing involvement of the right parotid gland by diffuse infiltrative lymphocytosis syndrome (DILS).

Image described by caption.

      Antibiotics account for approximately 80% of all medications prescribed during pregnancy and approximately 20–55% of women will receive an antibiotic during pregnancy (Bookstaver et al. 2015). Although the use of an oral or intravenous antibiotic during pregnancy is a risk–benefit decision‐making exercise, any untreated infection is associated with significant fetal risk including spontaneous abortion, low birth rate, and prematurity. That said, antibiotic exposure during pregnancy may result in short‐term and long‐term effects on infant weight, specifically lower birth weight; childhood obesity; neurologic disease, including cerebral palsy and epilepsy; and childhood asthma (Bookstaver et al. 2015).

      In addition to fetal safety related to antibiotic use during pregnancy, there are physiologic changes in pregnancy that may lead to pharmacokinetic changes and impact pregnancy. For example, increases in total body water, blood volume (40–50%), and plasma volume (40–50%) contribute to increases in volume of distribution of various antibiotics. Renal blood flow increases by 50%, serum creatinine decrease, and glomerular filtration rate increases elimination of renally excreted antibiotics. Changes in gastrointestinal motility may alter absorption, oral bioavailability, and delayed onset of action of certain antibiotics. The beta‐lactam antibiotics, vancomycin, metronidazole, and clindamycin are generally considered safe in pregnancy, while fluoroquinolones and tetracyclines are generally avoided in pregnancy (Bookstaver et al. 2015). In the final analysis, consultation with the pregnant women's obstetrician is recommended when antibiotics are required for the treatment of sialadenitis.

      Collectively, the collagen vascular diseases, including polymyositis, dermatomyositis, scleroderma, and systemic lupus erythematosus, may all affect the salivary glands, although Sjogren disease and sarcoidosis are most commonly responsible (Kessler and Bhatt 2018). Sjogren disease‐related sialadenitis is predominantly seen in females and most commonly in postmenopausal women (50–70 years of age). A juvenile subtype is seen in men younger than 20 years of age that typically resolves at puberty. Sjogren disease‐related sialadenitis is classified into two types. Sjogren type 1 disease (Mikulicz disease or sicca syndrome without a connective disorder) refers to autoimmune sialadenitis without a systemic collagen vascular disorder. These patients demonstrate xerostomia and are incorporated into the IgG4 spectrum of disease. Sjogren type 2 disease refers to autoimmune inflammation of the salivary glands with a systemic autoimmune diagnosis (rheumatoid arthritis > systemic lupus erythematosus > scleroderma).

      Systemic lupus erythematosus is most frequently seen in fourth and fifth‐decade women. Any of the salivary glands may become involved, and a slowly enlarging gland is the presentation. The diagnosis is made by identification of the underlying systemic disorder, and salivary chemistry levels will reveal sodium and chloride ion levels that are elevated to two three times normal levels (Miloro and Goldberg 2002).

      Sarcoid‐related sialadenitis is seen in 10–30% of patients with sarcoidosis and patients typically present with painless bilateral parotid swelling. The treatment of autoimmune sialadenitis involves treatment of the responsible systemic disease. The reader is referred to Chapter 6 in which autoimmune sialadenitis is more granularly reviewed and illustrated.


Скачать книгу